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INTRODUCTION
According to the WHO, approximately 120 million cases of COVID-19 have been confirmed
worldwide, with almost 3 million deaths recorded on April 8th, 2021 [https://covid19.who.int/].
Clinically, COVID-19 ranges from an asymptomatic infection to a severe illness, in which patients
require mechanical ventilation and hospitalization. Case fatality rates range from <1% up to 20%,
and are heavily influenced by patient age, comorbidities [https://ourworldindata.org], as well as
geographic location [https://coronavirus.jhu.edu/data/mortality]. In severe and critical patients
older than 75 years, case fatality reaches 79.2% (1). Poor outcome patients frequently present
progressive pulmonary infiltrates and hyperinflammatory response (2), which are targets of
different experimental treatment strategies.
So far, there is no consensus on the standard treatment for critical COVID-19 patients. An
overwhelming number of parallel developments are currently underway with this objective,
including the administration of Mesenchymal Stem Cells (MSCs) and MSC-derived products,
such as exosomes. The low levels of ACE-2 and TMPRSS2 on the MSC surface, the refractory profile
of these cells when challenged with SARS-CoV-2 (3), and the successful use of MSCs to treat
inflammatory disorders justify the investigation of MSCs and their products for COVID-
19 management.
In July 2020, we provided a comprehensive analysis of the clinical trials underway worldwide
investigating the application of stem cells and derived products to treat COVID-19 (4). At the time,
69 clinical trials had been initiated, but only 3 scientific publications and 3 company press release
documents had been published reporting achieved results.org April 2021 | Volume 12 | Article 6821951
Carvalho et al. MSCs and COVID-19 2021 UpdatesDuring the last 8 months, 40 new clinical trials involving
MSC-based treatments for COVID-19 were registered, and 8
scientific publications have been published. Such an update
consti tutes an important addit ion to the previous
comprehensive review, bringing additional data on more than
160 COVID-19 patients which have successfully received MSC
and MSC-derived products. Therefore, in this general
commentary, we provide an updated analysis of the current
evidence regarding the use of stem cells and derived products for
COVID-19 treatment with the aim of filling the present
knowledge gap regarding the robust demonstration of theFrontiers in Immunology | www.frontiersin.org 2feasibility, safety and possible efficacy of such therapeutic
alternatives for COVID-19 management.NEW EVIDENCES REGARDING THE USE
OF STEM CELLS AND DERIVED
PRODUCTS
Among the 8 scientific publications detected by our group during
the last 8 months (Table 1), 7 report clinical results of MSC-














No adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was
observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill
though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Patients’
clinical status and oxygenation improved. Significant improvements in absolute neutrophil count and
lymphopenia. Mean C-reactive protein, ferritin, and D-dimer reduction of 77%, 43% and 42%,
respectively.
(5)





UC-MSCs Three doses of
3 × 107 cells
per infusion,
intravenous
No serious adverse events were observed. Mechanical ventilation was required in 1 of 9 patients in
the treatment group compared with 4 of 9 in the control group. All patients recovered and were






UC-MSCs Single dose of
2 × 106 cells/kg
intravenous
In the 28-day mortality rate were 0 of 12 patients in the hUC-MSC treatment group, while 4 of 29
patients in the control group deteriorated to critical condition and received invasive ventilation; 3
of them died. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the
lymphocyte count to return to the normal range was significantly faster, and lung inflammation













Significant reductions in serum levels of TNF-a, IL-8 and C-reactive protein (CRP) were seen in all
six survivors (a total of 11 patients received MSCs infusion). IL-6 levels decreased in five patients
and IFN-g levels decreased in four patients. Four patients who had signs of multi-organ failure or
sepsis died in 5–19 days after the first MSC infusion. All 6 survivors were well with no complaints of
dyspnea on day 60 post-infusion. Radiological parameters of the lung computed tomography (CT)
scans showed remarkable signs of recovery.
(8)




UC-MSCs Two doses of
100 ± 20 X106
cells,
intravenous
No serious adverse events (SAEs) were observed in the 12 patients who received UC-MSC
infusions. UC-MSC infusions were found to be safe. Inflammatory cytokines were significantly
decreased in UC-MSC-treated subjects on day 6. Treatment was associated with significantly
improved patient survival, SAE-free survival, and lower time to recovery.
(9)
NCT04288102 - Phase 2
Randomized, double-blind,
placebo-controlled
UC-MSCs Three doses of
4 × 107,
intravenous
A total of 65 patients received MSCs infusion. UC-MSCs administration exerted improvement in
whole lung lesion volume compared with placebo. The 6-minute walk test showed an increased
distance in patients treated with UC-MSCs. The incidence of adverse events was similar in the two
experimental groups.
(10)
NCT04269525 - Phase 2
Single Group Assignment
UC-MSCs Four doses,
total of 1 × 108
cells,
intravenous
A total of 16 patients received MSCs infusions. There were no infusion-related or allergic reactions.
The oxygenation index was improved after cell transplantation. The mortality of enrolled patients
was 6.25%, whereas the historical mortality rate was 45.4%. The level of cytokines estimated varied
in the normal range, the radiological presentations (ground glass opacity) were improved, the
lymphocyte count and lymphocyte subsets (CD4+ T cells, CD8+ T cells and NK cells) count
showed recovery after cell therapy.
(11)
Not informed - Single
Group Assignment




Clinical improvement was observed in 9 of 13 patients. No adverse events were related to cell
therapy. Seven patients were extubated and discharged from ICU while four patients remained
intubated. Two patients died (one due to gastrointestinal bleeding unrelated to MSC therapy).
Treatment with AT-MSC was followed by a reduction in C-reactive protein, IL-6, ferritin, LDH and
D-dimer.
(12)April 2021 | Volume 12 | Article 682MSCs, Mesenchymal Stem Cells; AT-MSCs, Adipose Mesenchymal Stem Cells; PL-MSCs, Placental Mesenchymal Stem Cells; UC-MSCs, Umbilical cord Mesenchymal Stem Cells.195
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of 162 COVID-19 patients, constituting a more robust body of
evidence supporting the safety and efficacy profile of MSCs and
their products, especially for critical patients.
Study Characteristics
In our original study published in July 2020, we identified 13
phase 1, 13 phase 2, 19 phase 1/2, 1 phase 2/3 and 1 phase 3
study. Since then, the clinical phase of published studies is now
more advanced and includes the publication of a primary report
of a 2/3 study. Nevertheless, most of the newly identified trials
are still in phase 1 and phase 2 studies, and the information
regarding 6 out of 40 trials was not clear.
Most clinical studies underway consist of randomized trials.
Most frequently, the control groups include placebo and routine
treatment. Some studies still lack control groups, and 1 study is a
single center, retrospective investigation.
Cell-based therapy remains the most explored therapeutic
strategy. While 38 studies intend to investigate the use of MSCs
to treat COVID-19, two studies focus on the use of MSC-derived
products (NCT04602442 and NCT04753476). Thirty-four will
administer the cells intravenously. One study proposed the
inhalatory route for exosome treatment, and one study
proposed the intramuscular route for MSC-secretome
administration. The proposed number of infused cells was
similar to previously detected, ranging between 0.5x106 and
3x108 cells, with the most frequently proposed dose consisting
of single or multiple infusions of 1x106 cells/kg.
In the MSC source side, the umbilical cord was the most
commonly chosen MSC source (27%), as previously noticed,
followed by the bone marrow (20%), adipose tissue (15%), dental
pulp (7.5%), Wharton’s jelly (5%), placenta and amniotic
membrane (1 study each).
Considering published results, the 8 new scientific publications
detecteddescribe thedataobtained from160patientswhich received
MSC-based advanced therapies for COVID-19 management.
Different from the scarce safety and efficacy evidence observed in
July 2020, the current evidence supporting the notion thatMSC and
MSC-derived therapeuticproducts are safe andeffective arebasedon
the reports of several different research groups distributed
worldwide. The most prominent beneficial effects of MSC and
MSC-derived therapeutic products include the improvement of
patient breathing capacity, the mitigation of cytokine storms, the
restoration of the immune system, the decrease of hospitalization
time, and the increase in patient survival rates.
DISCUSSION
The COVID-19 pandemic has provoked a rapid mobilization of
the scientific community in the attempt of providing control,
prevention, and treatment strategies for COVID-19. In the
absence of a gold-standard treatment for the disease (13), it is
important for physicians to keep the pace regarding the real
evidence supporting different experimental treatment strategies.
For instance, as reported by Servick et al., in the last few months,
“physicians memorized treatment guidelines one day only to
learn they’d changed the next” (14).Frontiers in Immunology | www.frontiersin.org 3Since July 2020, important data have been published
demonstrating that the use of MSCs for severe COVID-19
treatment is increasingly promising. In the last 8 months, more
than 160 patients received MSC and MSC-derived therapies. In
contrast to the 51 patients treated with MSC-based advanced
therapies for COVID-19 between January and July 2020, current
evidence is now based on the data obtained from more than 200
COVID-19patients. Importantly, thepublisheddata available at this
point clearly indicates that the infusion ofMSCs is feasible, safe, and
that it possibly constitutes a highly effective treatment option for
severe cases of COVID-19. Evidently, a final conclusion regarding
the effects ofMSCs administration and its products on themortality
of patients with COVID-19 depends on the complete data of large,
randomized phase 3 trials, which are eagerly awaited (14).
Possibly due to the successful data obtained at this point, no
important differences were detected considering the clinical trial
design, MSC source, dose, and administration route proposed by
the latest clinical studies registered in clinical trial databases.
As discussed in our first manuscript, the proposal of treating
COVID-19 patients with MSC and MSC-products derive from
the partial knowledge regarding the COVID-19 pathophysiology,
but also from previous experience in the treatment of other
respiratory diseases, such as influenza. Therefore, it is important
to acknowledge the importance of accumulating clinical
experience in the use of MSCs, in order to rapidly expand its
application in times of need. It is indeed possible that the
immunization of the world’s population will constitute
the main strategy to prevent COVID-19 spread, and that the
current treatment alternatives based on dexamethasone,
Remdesivir, and monoclonal antibodies (13–15), will possibly
decrease the need for advanced therapies for COVID-19.
Still, it is important to acknowledge that, especially for critically
ill patients, COVID-19 importantly affects multiple organs (16), in
such an extent that these patients are beyond the point where
antiviral alternatives might restore organismal function. In this
scenario, the pleiotropic and systemic anti-inflammatory and
regenerative effects of stem cells may greatly benefit severe
patients, justifying further investigation (17). Regardless of stem
cell treatment becoming the gold standard for severe COVID-19,
the lessons learned by the regenerative medicine research
community in the short period of the last 15 months will be
forever useful for future therapeutic applications of such products.AUTHOR CONTRIBUTIONS
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